01/22/2026
🔰New research is giving us clearer insight into agitation in Alzheimer’s disease.
A recent clinical trial looked at whether escitalopram (an antidepressant) could help with agitation — and it didn’t show benefit. But the bloodwork told a much more interesting story.
🧬A simple blood marker called p‑tau217 confirmed Alzheimer’s changes in the brain for 94% of participants. Even more importantly, people with higher levels of this marker tended to have:
- more severe agitation
- more worsening agitation over time
- lower cognitive scores
Another marker, GFAP, also tracked with lower cognitive functioning.
❓What does this mean for families❓
🌟Blood biomarkers are becoming powerful tools for understanding where someone is in the disease process and why certain symptoms, like agitation, may be more challenging for some individuals. The FDA authorized blood tests that include p‑tau217 for use in evaluating symptomatic Alzheimer’s disease in 2025. They’re not used everywhere yet, but they’re shaping the future of dementia care and research.🌟
📞If you’re caring for someone with dementia and want help making sense of what all this means in real life, I’m here
Barnwal M, Baksh S, Ismail Z, Shade DM, Moghekar A, Ho SG, Rosenberg PB, Porsteinsson AP, Lyketsos CG; S‐CitAD Research Group. Blood biomarkers for Alzheimer's disease are correlated with measures of agitation and cognition in a randomized trial assessing the effects of escitalopram on agitation. Alzheimers Dement (N Y). 2026 Jan 18;12(1):e70203. doi: 10.1002/trc2.70203. PMID: 41560713; PMCID: PMC12812854.
.